Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAZOLAMIDE SODIUM vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Treatment of open-angle glaucoma and secondary glaucoma,Preoperative and perioperative reduction of intraocular pressure in acute angle-closure glaucoma,Treatment of edema due to congestive heart failure when other diuretics are ineffective,Adjunctive treatment of epilepsy (centrencephalic epilepsies, absence seizures),Prophylaxis and treatment of acute mountain sickness
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
10-15 hours (prolonged in renal impairment; cirrhosis increases t1/2 to 20-30 h).
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Acetazolamide is minimally metabolized in the liver, with the majority of the drug excreted unchanged in the urine. The primary metabolic pathway involves oxidation of the thiadiazole ring, but this is a minor route. The drug is not extensively biotransformed; hepatic metabolism accounts for less than 10% of elimination.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily renal (90% unchanged via tubular secretion). <2% biliary/fecal.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
70-90% (mainly carbonic anhydrase in RBCs; low affinity for albumin).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 0.2-0.3 L/kg; mainly confined to extracellular fluid and highly perfused tissues.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: ~90-100% (rapidly absorbed; food may delay). Intramuscular: not recommended (acidic p H).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 10-50 m L/min: administer every 12 hours. GFR <10 m L/min: avoid or use with extreme caution.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or extend interval to 24-48 hours. Child-Pugh C: avoid use.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
For edema: 5 mg/kg IV or IM once daily. For glaucoma: 10-15 mg/kg/day IV or IM in divided doses every 6-8 hours.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at lowest adult dose; monitor renal function and electrolytes; adjust based on creatinine clearance.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Use with caution in patients with hepatic cirrhosis, as acetazolamide can precipitate hepatic encephalopathy due to increased ammonia levels,May cause metabolic acidosis, which can be severe with prolonged use; monitor serum electrolytes and bicarbonate levels,Can precipitate renal calculi due to decreased urinary citrate excretion; ensure adequate hydration,May cause drowsiness, confusion, or ataxia; caution when operating machinery or driving,Use with caution in patients with respiratory acidosis or chronic obstructive pulmonary disease, as metabolic acidosis may worsen respiratory function,Monitor for signs of hypersensitivity reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis,May cause hematologic reactions such as agranulocytosis, aplastic anemia, and thrombocytopenia; monitor blood counts
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Known hypersensitivity to acetazolamide or any sulfonamide-derivative (although cross-reactivity may not occur, caution is advised),Severe hepatic insufficiency or cirrhosis with risk of hepatic encephalopathy,Severe renal impairment (e.g., anuria, glomerular filtration rate <10 m L/min),Metabolic acidosis,Hyponatremia or hypokalemia,Concurrent use with high-dose aspirin (risk of metabolic acidosis and increased salicylate toxicity)
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food interactions reported. However, high-sodium foods may counteract the diuretic effect. Maintain adequate fluid intake to prevent kidney stones. Avoid large amounts of caffeine as it may increase diuresis and electrolyte loss.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Acetazolamide is contraindicated in pregnancy (FDA category C). First trimester: associated with increased risk of neural tube defects and limb anomalies in animal studies; human data limited but suggests potential teratogenicity. Second and third trimesters: may cause fetal metabolic acidosis, electrolyte disturbances, and growth restriction due to carbonic anhydrase inhibition.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Acetazolamide is excreted into breast milk in low amounts. M/P ratio is approximately 0.25. Infant exposure is minimal but may cause metabolic acidosis or diuresis. Caution is advised; monitor infant for signs of acidosis or dehydration.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Dose adjustments may be necessary due to increased renal clearance and volume of distribution in pregnancy. Monitor therapeutic effect and adverse reactions; consider starting at lower doses and titrating based on response. No standardized guidelines exist; individualize therapy.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Acetazolamide is a carbonic anhydrase inhibitor used for altitude sickness prophylaxis, glaucoma, and as a diuretic. Monitor for metabolic acidosis, especially in elderly or renal impairment. Can cause hypokalemia; check serum potassium. Contraindicated in hepatic cirrhosis due to risk of hepatic encephalopathy. May cause paresthesias, especially in hands and feet, which are harmless but can be distressing.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take with food to reduce gastrointestinal upset.,May cause tingling in fingers, toes, or face; this is usually temporary and not harmful.,Drink plenty of fluids unless otherwise instructed to prevent kidney stones.,Avoid alcohol as it may increase side effects like dizziness.,Do not drive or operate machinery until you know how this medication affects you, as it may cause drowsiness or blurred vision.,Report any signs of unusual bleeding, bruising, or signs of infection to your healthcare provider.,Take exactly as prescribed; do not stop suddenly without consulting your doctor.,If used for altitude sickness, start 24-48 hours before ascent and continue for 48 hours at high altitude.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Bosutinib, a potent CYP3A4 inhibitor, can significantly increase the serum concentration of acetazolamide, a carbonic anhydrase inhibitor, by reducing its hepatic metabolism. This elevation may potentiate acetazolamide's adverse effects, including metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and paresthesias, especially in patients with renal impairment. Clinicians should monitor for signs of acetazolamide toxicity when coadministered with bosutinib."
"Acetazolamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and decrease renal tubular secretion of metformin, potentially increasing metformin plasma concentrations. This combination may elevate the risk of lactic acidosis, a rare but serious adverse effect of metformin. Additionally, acetazolamide-induced hypokalemia can exacerbate metformin-associated hyperlactatemia."
"Acetazolamide, a carbonic anhydrase inhibitor, increases urinary pH and promotes bicarbonate excretion, leading to metabolic alkalosis. This systemic alkalinization enhances renal tubular reabsorption of lithium, paradoxically decreasing lithium clearance and increasing serum lithium concentrations. Clinically, this can precipitate lithium toxicity, manifesting as nausea, tremor, ataxia, or confusion, particularly in patients on stable lithium regimens."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAZOLAMIDE SODIUM vs ABSTRAL, answered by our medical review team.
ACETAZOLAMIDE SODIUM is a Carbonic Anhydrase Inhibitor that works by Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAZOLAMIDE SODIUM and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAZOLAMIDE SODIUM is: Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAZOLAMIDE SODIUM and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAZOLAMIDE SODIUM is classified as Category C. Acetazolamide is contraindicated in pregnancy (FDA category C). First trimester: associated with increased risk of neural tube defects and limb anomalies in animal studies; human d. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.